questionText: To ask the Secretary of State for Health and Social Care, with reference to HCWS1248, what estimate has been made of the annual cost to the NHS of expanding access to abiraterone; what savings have been achieved through the availability of generic version
answerText: Approximately 2,000 men diagnosed in the last three months with non‑metastatic prostate cancer will now be able to receive abiraterone where it is of clinical benefit, alongside prednisolone. An additional 7,000 men are expected to be diagnosed with prost...
heading: Prostate Cancer: Abiraterone